静脉注射免疫球蛋白治疗儿童川崎病的循证指南(2023)  

Evidence-based guideline for intravenous immunoglobulin treatment of Kawasaki disease in children(2023)

作　　者：雷文娟 周奇[5] 高琲[1,3,4] 赵俊贤 刘辉 田敏 贾忠 王荣 虎亚光 魏玉辉[13] 杨彦彪[15] 张红梅 戴永利 周素琴 刘静[19] 王法琴[17] 雷晓燕[2] 王建军[1] 陶仲宾[14] 杨轶男[17] 王卫凯[18] 徐瑞峰 马建丽[8] 张海平[20] 李丽亚[21] 汤兴萍 王向东 李哲玮[5,6] 邵婷玑 辛明彦 孟敏 葛斌[1,3,4] Lei Wenjuan;Zhou Qi;Gao Bei;Zhao Junxian;Liu Hui;Tian Min;Jia Zhong;Wang Rong;Hu Yaguang;Wei Yuhui;Yang Yanbiao;Zhang Hongmei;Dai Yongli;Zhou Suqin;Liu Jing;Wang Faqin;Lei Xiaoyan;Wang Jianjun;Tao Zhongbin;Yang Yinan;Wang Weikai;Xu Ruifeng;Ma Jianli;Zhang Haiping;Li Liya;Tang Xingping;Wang Xiangdong;Li Zhewei;Shao Tingji;Xin Mingyan;Meng Min;Ge Bin(Department of Pharmacy,Gansu Provincial Hospital,Lanzhou 730000,China;Gansu Provincial Hospital,Lanzhou 730000,China;The Technology Center for Comprehensive Clinical Evaluation of Medicines in Gansu Province,Health Commission of Gansu Province,Lanzhou 730000,China;Pharmacoeconomics Committee,Gansu Pharmaceutical Association,Lanzhou 730030,China;Evidence-based Medicine Center,School of Basic Medical Sciences,Lanzhou University,Lanzhou 730000,China;School of Public Health,Lanzhou University,Lanzhou 730000,China;Department of Pharmacy,The Second People's Hospital of Lanzhou City,Lanzhou 730000,China;Department of Pediatric,The Second People's Hospital of Lanzhou City,Lanzhou 730000,China;Department of Pharmacy,The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army,Lanzhou 730000,China;Department of Pediatric,The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army,Lanzhou 730000,China;Department of Pharmacy,Gansu Provincial Maternity and Child-care Hospital,Lanzhou 730050,China;Department of Pediatric,Gansu Provincial Maternity and Child-care Hospital,Lanzhou 730050,China;Department of Pharmacy,The First Hospital of Lanzhou University,Lanzhou 730000,China;Department of Pediatric,The First Hospital of Lanzhou University,Lanzhou 730000,China;Department of Pharmacy,The First People's Hospital of Lanzhou City,Lanzhou 730050,China;Department of Pharmacy,The Second People's Hospital of Gansu Province,Lanzhou 730000,China;Department of Pharmacy,The Second Hospital of Lanzhou University,Lanzhou 730030,China;Department of Pediatric,The Second Hospital of Lanzhou University,Lanzhou 730030,China;Department of Pharmacy,J

机构地区：[1]甘肃省人民医院药剂科,甘肃兰州730000 [2]甘肃省人民医院儿科,甘肃兰州730000 [3]甘肃省卫生健康委员会甘肃省药品临床综合评价技术中心,甘肃兰州730000 [4]甘肃省药学学会药物经济学专业委员会,甘肃兰州730030 [5]兰州大学基础医学院循证医学中心,甘肃兰州730000 [6]兰州大学公共卫生学院,甘肃兰州730000 [7]兰州市第二人民医院药剂科,甘肃兰州730000 [8]兰州市第二人民医院儿科,甘肃兰州730000 [9]联勤保障部队第九四○医院药剂科,甘肃兰州730000 [10]联勤保障部队第九四○医院儿科,甘肃兰州730000 [11]甘肃省妇幼保健院药学部,甘肃兰州730050 [12]甘肃省妇幼保健院儿科,甘肃兰州730050 [13]兰州大学第一医院药剂科,甘肃兰州730000 [14]兰州大学第一医院儿科,甘肃兰州730000 [15]兰州市第一人民医院药剂科,甘肃兰州730050 [16]甘肃省第二人民医院药剂科,甘肃兰州730000 [17]兰州大学第二医院药剂科,甘肃兰州730030 [18]兰州大学第二医院儿科,甘肃兰州730030 [19]酒泉市人民医院药剂科,甘肃酒泉735000 [20]兰州市妇幼保健院药剂科,甘肃兰州730000 [21]临夏州人民医院儿科,甘肃临夏731100 [22]河西学院附属张掖人民医院儿科,甘肃张掖734000 [23]天水市第一人民医院儿科,甘肃天水741000

出　　处：《兰州大学学报（医学版）》2024年第1期52-60,81,共10页Journal of Lanzhou University（Medical Sciences）

基　　金：甘肃省人民医院院内科研基金资助项目(23GSSYC-8);2021年度甘肃省药品临床综合评价工作资助项目。

摘　　要：川崎病(KD)在中国发病率逐年增高,静脉注射免疫球蛋白(IVIG)是KD的一线治疗方案。目前关于KD的指南多侧重于临床诊断,IVIG治疗KD的指南缺乏多学科循证证据支持。本指南遵循《世界卫生组织指南制订手册》和《中国制订/修订临床诊疗指南的指导原则(2022版)》,通过问卷调研儿科医师和临床药师,确定10个临床问题。基于国内外现有证据,同时考虑中国患者的偏好与价值观、干预措施的成本、利弊和可及性等因素,通过德尔菲法调研,最终形成关于IVIG治疗儿童KD的10条推荐意见。本指南适用于各级医院从事KD相关工作的临床医师和临床药师。The incidence of Kawasaki disease(KD)has increased in China,and intravenous immunoglobulin(IVIG)is a first-line treatment for KD.Current guidelines on KD mostly focus on its diagnosis,while guidelines on IVIG for KD still lack evidence support.This guideline refers to the World Health Organisation Handbook for Guideline Development and Guidelines for the Development/Revision of Clinical Practice Guidelines in China(2022 edition).In this study a questionnaire was administered to pediatricians and clinical pharmacists to identify 10 clinical questions.Ten recommendations on IVIG for KD in children were finalized through Delphi based on available evidence,as well as the values of patient preferences,the cost,the balance of pros and cons,and accessibility of interventions.The guideline is applicable to clinicians and pharmacists working on KD in all levels of hospitals.

关 键 词：儿科 川崎病 静脉注射免疫球蛋白 循证指南 

分 类 号：R725.4[医药卫生—儿科] R969.3[医药卫生—临床医学]